Hirudin for Prophylaxis and Treatment of Deep Vein Thrombosis

 

 Buy Article Permissions and Reprints

ABSTRACT

Since recombinant hirudin (r-hirudin) has become available, several studies have been published on hirudin for prophylaxis and treatment of thromboembolic complications. Vr-hirudin was shown to be superior even to low-molecular-weight heparin (LMWH) for prophylaxis of deep venous thrombosis (DVT), especially in high-risk patients. Consequently, r-hirudin was expected to be more effective than heparins are in the treatment of thromboembolic events. Vr-hirudin was proved to be safe and efficacious in the therapy of thromboembolic events. However, no benefit could be shown in comparison with heparin. In contrast, in patients suffering from HIT type II, r-hirudin is the drug of choice for the therapy of thromboembolic complications.

REFERENCES

• 1 Parent S, Bridey F, Dreyfus M. Treatment of severe thromboembolism with intravenous hirudin (HBW 023): an open pilot study.  Thromb Haemost . 1993;  70 386-388
  PubMedGoogle Scholar
• 2 Eriksson B, Kälebo P, Ekman S. Direct thrombin inhibition with rec-hirudin (CGP 39 393) as prophylaxis of thromboembolic complications after total hip replacement.  Thromb Haemost . 1994;  72 227-231
  PubMedGoogle Scholar
• 3 Eriksson B, Ekman S, Kälebo P. Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin CGP 39 39393.  Lancet . 1996;  347 635-639
  CrossrefPubMedGoogle Scholar
• 4 Eriksson B, Ekman S, Lindbratt S. Prevention of thromboembolism with use of recombinant hirudin: results of a double-blind, multicenter trial comparing the efficacy of desirudin (REVASC) with that of unfractionated heparin in patients having a total hip replacement.  J Bone Joint Surg . 1997;  79-A 326-333
  PubMedGoogle Scholar
• 5 Eriksson B, Wille-Jørgensen P, Kälebo P. A comparison of recombinant hirudin with a low molecular weight heparin to prevent thromboembolic complications after total hip replacement.  N Engl J Med . 1997;  337 1329-1335
  CrossrefPubMedGoogle Scholar
• 6 Matzdorff A, Kemkes-Matthes B. Desirudin-recombinantes Hirudin zur Thromboseprophylaxe.  Arzneimitteltherapie . 1999;  17 146-148
  PubMedGoogle Scholar
• 7 Eriksson B I. New therapeutic options in deep vein thrombosis prophylaxis.  Semin Hematol . 2000;  37(Suppl 5) 7-9
  PubMedGoogle Scholar
• 8 Wille-Jørgensen P. New therapeutic options in DVT prophylaxis.  Orthopedics . 2000;  23(Suppl) 639-642
  PubMedGoogle Scholar
• 9 Huhle J F, Hoffmann U, Hoffmann I, Harenberg J, Heene D L. Thromboseprophylaxe mittels subkutanem rekombinantem Hirudin bei Heparin-induzierter Thrombozytopenie Typ II. Eine Pilotstudie.  Dtsch Med Wochenschr . 2000;  125 686-691
  PubMedGoogle Scholar
• 10 Schiele F, Vuillemenot A, Kramarz P h. A pilot study of subcutaneous recombinant hirudin (HBW 023) in the treatment of deep vein thrombosis.  Thromb Haemost . 1994;  71 558-562
  PubMedGoogle Scholar
• 11 Schiele F, Lindgaerde F, Eriksson H, for the International Multicenter Hirudin Study group. Subcutaneous recombinant hirudin (HBW 023) versus intravenous sodium heparin in treatment of established acute deep vein thrombosis of the legs: a multicenter prospective dose-ranging randomized trial.  Thromb Haemost . 1997;  77 834-838
  PubMedGoogle Scholar
• 12 Schenk J F, Berg G, Mörsdorf S. Heparin-induced thrombocytopenia: a critical risk/benefit analysis of patients in intensive care treated with r-hirudin.  Clin Appl Thromb Hemost . 2000;  6 151-156
  PubMedGoogle Scholar